Laurus Labs Limited

rs,

ovember 24, 2023 To To The Corporate Relations Department BSE Limited Phiroz Jeejeebhoy Towers, 25th Floor, Dalal Street Mumbai – 400001 Code: 540222 The Listing Department National Stock Ex

₹ 6,041

10 # Audits Regulatory 2 5 (0 CF3) Clients 80 11 (0 CF) 171 20 (0 CF) 389 8 (0 CF) 298 ₹ 6,041 Cr Revenues 26.4% EBITDA As on FY 2023 API Active pharma ingredients 43%* CDMO Contract Devel

26.4%

ry 2 5 (0 CF3) Clients 80 11 (0 CF) 171 20 (0 CF) 389 8 (0 CF) 298 ₹ 6,041 Cr Revenues 26.4% EBITDA As on FY 2023 API Active pharma ingredients 43%* CDMO Contract Development & Manufactur

43%

8 (0 CF) 298 ₹ 6,041 Cr Revenues 26.4% EBITDA As on FY 2023 API Active pharma ingredients 43%* CDMO Contract Development & Manufacturing Services 36% FDF Formulation/Drug Product 19% BIO

36%

FY 2023 API Active pharma ingredients 43%* CDMO Contract Development & Manufacturing Services 36% FDF Formulation/Drug Product 19% BIO Biotechnology 2% Creating value proposition for stakehold

19%

ents 43%* CDMO Contract Development & Manufacturing Services 36% FDF Formulation/Drug Product 19% BIO Biotechnology 2% Creating value proposition for stakeholders with Focus on business diversif

2%

t Development & Manufacturing Services 36% FDF Formulation/Drug Product 19% BIO Biotechnology 2% Creating value proposition for stakeholders with Focus on business diversification and operational

₹ 2,056

ng business growth Strong growth through robust model Diversification of Laurus business FY 18 ₹ 2,056 Cr FY 23 ₹ 6,041 Cr [₹ Crores] 125 1 1972 6,041 402 744 742 2,056 +18% CAGR (ex PO1) +

18%

iness FY 18 ₹ 2,056 Cr FY 23 ₹ 6,041 Cr [₹ Crores] 125 1 1972 6,041 402 744 742 2,056 +18% CAGR (ex PO1) + 24% CAGR on reported basis FY 18 ARV API (Onco+Others) FDF (ex-ARV) CDMO BI

24%

Cr FY 23 ₹ 6,041 Cr [₹ Crores] 125 1 1972 6,041 402 744 742 2,056 +18% CAGR (ex PO1) + 24% CAGR on reported basis FY 18 ARV API (Onco+Others) FDF (ex-ARV) CDMO BIO ^ FY 23 ^ Reflect

37%

to Big Pharma in FY23, the order was completed on Dec-22 6 Investor Presentation | November 2023 37%18%7%36%2%ARVAPI (Onco+Others)FDF (ex-ARV)CDMOBioARV73% Enabling customer with our Leading commercia

7%

Pharma in FY23, the order was completed on Dec-22 6 Investor Presentation | November 2023 37%18%7%36%2%ARVAPI (Onco+Others)FDF (ex-ARV)CDMOBioARV73% Enabling customer with our Leading commercial sca

“New platform being further explored  Complex Oral drug BETAF1 combo (INSTI inhibitor) and TAF filings under various stage of regulatory approval  LA-CAB1 Inj (PrEP and Treatment) project development initiated  New market access: 1) Access to South Africa market in next tender cycle and 2) India NACO tender – Already won 20% vol.”

“CDMO business project pipeline scaled up along with expansion of our strategic manufacturing partnerships   ₹ 2,406 Cr Revenues for H1, declined 23%.”

Chemical - expertise

1

Capacity Expansion

1

Chemical - expertise

Small molecules including HP APIs GMP intermediates, Chiral Chemistry, Peptides, Hazardous chemistry, Bio-cataysis Large scale – Chromatography incl. SMB, Cryogenic, Hydrogenation & Flow chemistry >> Offers Integrated approach Manufacturing & Quality Service Platform Technology 6 global regulatory agencies 1025+ quality audits 218 patents granted 75+ successful launch across DP/DS > > Analytical Services Life Cycle Management Microbial offering incl. HPAPIs within CMO Regulatory filings services Packaging Bio – expertise: Precision Fermentation (r-protein Food, Bio catalysis large scale) Oral Dosage forms & Delivery systems Cell & Gene Harnessing expertise across end market Human Health (Rx brands + Generics) Animal Health Crop Protection Food & Nutrition Making efficient use of technology platform and manufacturing excellence in the target market Transforming Laurus with Focus & Agility Laurus Evolution Key Capabilities One Product API Company Formulation Integrated Pharma 2006-2011 2

Capacity Expansion

 2x Oral dose capacity on-line (FDA approved)  Shell available for additional 5 Bn expansion 3 API – Deploy Technical capabilities with Focus on High growth segment Revenue Growth Strategic Priorities [₹ Cr] CAGR FY18-23: ▲7% 1H FY24: ▼3%  Accelerate cost leadership & Clear focus on commercial strategy  New CMO partnership in established and high growth molecules (like Diabetic / CV portfolio, Gastro)  Optimize new capacities in mid-term      Sufficient capacity to maximize market opportunities Strengthen leadership in Highly-potent APIs driven by Oncology Recent Highlights Scaled-up in the exiting CMO partnered projects; Strong order book +25% development/commercial scale capacity added in last 18 months; focus on capacity filling Executing on Continuous Flow technology at large scale  H1 stable as steady ARV API and strong delivery in Oncology compensated for decline in Other API due to scheduling issue  Oncology business +50% in H1 on favorable demand dynamics. Upgrading